Astrazeneca Ab

Rolf Peter Walker

Michael James Waring

Stuart Norman Lile Bennett

Roger John Butlin

Roger James

Stuart Eric Pearson

Ulrik Jurva

Anthony Michael Slater

Graeme Richard Robb

Leonie Campbell

Christer Ralf Westerlund

Peter Gustaf Bonn

Peter Wr Caulkett

Helen Claire Pointon

Robert Darren Morse Davies

Mikael Dan Brink

Jonas Rickard Fägerhag

Volker Schnecke

Anette Marie Svensson Henriksson

A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

Therapeutic agents

(2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

The invention relates to heterocyclic derivatives of formula (I), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocyclic derivatives which inhibit factor Xa

Growing community of inventors

Macclesfield, United Kingdom

Rolf Peter Walker